Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

giredestrant

An orally available selective estrogen receptor degrader/downregulator (SERD), with potential antineoplastic activity. Upon oral administration, giredestrant specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that promotes ER degradation. This prevents ER-mediated signaling and inhibits both the growth and survival of ER-expressing cancer cells.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	selective estrogen receptor degrader GDC-9545 selective estrogen receptor downregulator GDC-9545 SERD GDC-9545
Code name:	GDC 9545 GDC-49545 RG6171

giredestrant

Search NCI's Drug Dictionary